Opdivo® (nivolumab) – Expanded indication
March 11, 2020 - Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab), as a single agent or in combination with Yervoy® (ipilimumab), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).
Top